# US 2008/0188640 A1 · Immunodeficiency recombinant poxvirus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188640 A1
- Document ID: US20080188640A1
- Status: Published application
- Kind: A1
- Application number: 11/891,027
- Filed: 2007-08-08
- Published: 2008-08-07
- Earliest claimed: 1991-03-07
- Inventors: Enzo Paoletti; James Tartaglia; William I. Cox; Robert Gallo; Genoveffa Franchini
- Web page: https://patentgrep.com/patent/US20080188640A1

## CPC

- C07K 14/005: from viruses
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- C07K 14/33: from Clostridium (G)
- C12N 15/86: Viral vectors
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/5254: {avirulent or attenuated}
- C07K 2319/00: Fusion polypeptide
- C12N 2710/16222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/16622: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/16722: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/24022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/24043: viral genome or elements thereof as genetic vector
- C12N 2710/24122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/24143: viral genome or elements thereof as genetic vector
- C12N 2730/10122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/13022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/15022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/12022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/18122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/18722: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/20122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/24022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/24122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/24143: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Attenuated recombinant viruses containing DNA encoding an immunodeficiency virus and/or CTL antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: HIV1gag(+pro) (IIIB), gp120(MN) (+transmembrane), nef (BRU)CTL, pol(IIIB)CTL, ELDKWA or LDKW epitopes, preferably HIV1gag(+pro) (IIIB), gp120(MN) (+transmembrane), two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL epitopes; or two ELDKWA in gp120 V3 or another region or in gp160. The two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL epitopes are preferably CTL1, CTL2, pol1, pol2 and pol3. The recombinant viruses and gene products therefrom and antibodies generated by the viruses and gene products have several preventive, therapeutic and diagnostic uses. DNA from the recombinant viruses are useful as probes or, for generating PCR primers or for immunization. Also disclosed and claimed are HIV immunogens and modified gp160 and gp120.

## Claims

### Claim at position 1

1-35. (canceled)

### Claim 36

A protein having an amino acid sequence comprising the amino acid sequence of HIV1 gp120, wherein the amino acid sequence of the gp120 is modified so as to contain an epitope not naturally occurring in HIV1 gp120.

### Claim 37 (depends on 36)

The protein of claim 36, wherein the epitope is a B-cell epitope.

### Claim 38 (depends on 36)

The protein of claim 36, wherein the amino acid sequence of the gp120 is modified in the V3 loop so as to contain the epitope.

### Claim 39 (depends on 38)

The protein of claim 38, wherein the epitope is a B-cell epitope.

### Claim 40 (depends on 38)

The protein of claim 38, wherein the epitope is ELDKWA or LDKW.

### Claim 41 (depends on 36)

The protein of claim 36, wherein the amino acid sequence of the gp120 is modified to contain at least one of HIV1gag(+ pro) (IIIB), gp120(MN) (+ transmembrane), nef(BRU)CTL, pol(IIIB)CTL, and ELDKWA or LDKW epitopes.

### Claim 42 (depends on 41)

The protein of claim 41, wherein the amino acid sequence of the gp120 is modified in the V3 loop to contain the epitope.

### Claim 43 (depends on 38)

The protein of claim 38, comprising the amino acid sequence identified as SEQ ID NO: 137, SEQ ID NO: 140 or SEQ ID NO: 143.

### Claim 44

The protein having the amino acid sequence identified as SEQ ID NO: 137, SEQ ID NO: 140 or SEQ ID NO: 143.

### Claim 45 (depends on 36)

A nucleic acid molecule comprising a nucleic acid sequence which encodes the protein of claim 36.

### Claim 46 (depends on 37)

A nucleic acid molecule comprising a nucleic acid sequence which encodes the protein of claim 37.

### Claim 47 (depends on 38)

A nucleic acid molecule comprising a nucleic acid sequence which encodes the protein of claim 38.

### Claim 48 (depends on 39)

A nucleic acid molecule comprising a nucleic acid sequence which encodes the protein of claim 39.

### Claim 49 (depends on 40)

A nucleic acid molecule comprising a nucleic acid sequence which encodes the protein of claim 40.

### Claim 50 (depends on 41)

A nucleic acid molecule comprising a nucleic acid sequence which encodes the protein of claim 41.

### Claim 51 (depends on 42)

A nucleic acid molecule comprising a nucleic acid sequence which encodes the protein of claim 42.

### Claim 52

A nucleic acid molecule comprising the nucleic acid sequence which encodes the amino acid sequence identified as SEQ ID NO: 137, SEQ ID NO: 140 or SEQ ID NO: 143.

### Claim 53 (depends on 52)

The nucleic acid molecule of claim 52 selected from the group consisting of the nucleic acid molecules identified as SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 141 and SEQ ID NO: 142.
